Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) growth accelerates
Q2 FY2026 weighted avg shares (diluted) of 56.03M shares rose 56.4% year over year, ahead of the +27.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 16.6% from the prior quarter. Over 3 fiscal years it compounded at +116.1% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +56.4% holds above the trailing-twelve-month pace of +27.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 37.79M USD
- Year-over-year change
- +13.4%
- 4-year CAGR
- +82.1%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.79M | +13.4% |
| FY2024 | 2024-12-31 | 33.31M | +546.4% |
| FY2023 | 2023-12-31 | 5.15M | +37.5% |
| FY2022 | 2022-12-31 | 3.75M | +9.1% |
| FY2021 | 2021-12-31 | 3.43M | — |
Weighted Avg Shares (Diluted) vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 weighted avg shares (diluted) of 44.91M shares is the 6th highest of the 10 companies compared; the peer median is 55.66M shares.
- Its year-over-year change of +27.5% is the 2nd highest of 10, against a peer median of +5.6%.
- Over three fiscal years its annual growth of +116.1% compares with a peer median of +30.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 199.36M | +24.0% | +14.0% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | 115.39M | +93.6% | +384.0% |
| LTM Jun 2026 | 67.85M | +14.4% | +34.2% | |
| LTM Mar 2026 | 65.6M | +4.1% | +30.0% | |
| FY2025 | 55.66M | +0.8% | +0.4% | |
| LTM Jun 2026 | 44.91M | +27.5% | +116.1% | |
| LTM Mar 2026 | 29.47M | +0.4% | +3.6% | |
| LTM Mar 2026 | 26.32M | +15.6% | +85.8% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
| LTM Mar 2026 | 12.78M | +5.6% | +56.9% | |
| Peer median (excluding DNTH) | 55.66M | +5.6% | +30.0% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.